Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma
Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
This is a Phase I dose escalation study of PXD101 administered orally. Oral belinostat will
be given once or twice daily at various dosing schedules to patients with solid tumors. Doses
will be escalated until the maximum tolerated dose (MTD) is identified. In parallel, a cohort
of lymphoma patients will be given oral belinostat on a discontinuous once daily dosing
schedule.